GLP-1 analogs have been repeatedly shown to cross the BBB, stimulate brain GLP-1 receptors, and modulate mitochondrial function, protein aggregation, neuroinflammation, synaptic plasticity, learning and memory in experimental models of Parkinson’s and Alzheimer’s disease (Athauda and Foltynie, 2016). This evidence concerns the gene GCG and Parkinson disease.